{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"34","upperLimit":"58","value":"46"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"}],"units":"Participants"}],"description":"Pathologic complete response (CR) is defined as absence of viable tumor in the TURBT specimen. Stable/No Response is defined as at least some disease evaluation tests were done (same tests as baseline) and status does not qualify for CR or Progression. Progression is defined as one or more of the following must occur: unequivocal progression of disease in the opinion of the treating physician. Appearance of any new lesion/site. Death due to disease without documented progression or symptomatic deterioration.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive 3 cycles (1 cycle = 21 days) of neoadjuvant chemotherapy (800 mg/m\\^2 of gemcitabine IV and 80 mg/m\\^2 of Paclitaxel IV on days 1 and 8 and Carboplatin IV on day 1), TURBT within 4-8 weeks of chemotherapy, option of proceeding with immediate cystectomy or observation.","id":"OG000","title":"Gemcitabine, Paclitaxel, Carboplatin Followed by Surgery"}],"paramType":"NUMBER","populationDescription":"All eligible patients who started treatment were included in the analysis","reportingStatus":"POSTED","timeFrame":"up to 12 weeks after registration (assessed within 8 weeks after completion of 3 cycles of chemotherapy )","title":"Pathologic Complete Response Rate by Transurethral Resection of Bladder Tumor (TURBT) and Imaging Studies After Chemotherapy","type":"PRIMARY","unitOfMeasure":"percentage of participants"}